Gateway for:

Member Countries

Helicobacter Pylori in Central Asia

#K-573


Problems in epidemiology, diagnosis and therapy of Helicobacter pylori in disease of digestive organs in Central Asia

Tech Area / Field

  • MED-DIS/Disease Surveillance/Medicine
  • BIO-MIB/Microbiology/Biotechnology

Status
8 Project completed

Registration date
09.08.2000

Completion date
05.05.2008

Senior Project Manager
Melnikov V G

Leading Institute
Kazakhstan National Medical University, Kazakstan, Almaty

Supporting institutes

  • Kazakhstan Medical Institute, Kazakstan, Almaty\nNational Biotechnology Center of Kazakstan / Research Institute for Biological Safety Problems, Kazakstan, Gvardeiski\nKazakh Scientific Center for Quarantine and Zoonotic Diseases, Kazakstan, Almaty

Collaborators

  • Baylor College of Medicine, USA, TX, Houston

Project summary

The goal of this project is determination of prevalence, diagnostic and treatment of Helicobacter pylori – associated diseases in Central Asia.

The presenting risk factors of Helicobacter pylori infection, transmission, clinical peculiarities of Helicobacter-associated diseases in Central Asia should be clarified. The treatment schemes and regimens for eradication of Helicobacter pylori infection should be developed according.

Helicobacter pylori is worldwide infection. The rate of this infection is increasing by the age, and more than 50% of the population even of the developed countries can be infected in elderly age (Dooley, Cohen, Fitzgibbons, 1989). Typically, this infection is acquired in the childhood. There is the high prevalence of H.pylori infection the developing world.

This bacterium can be found in mucus in-patients with duodenal ulcer disease in 100% of cases, and in 80-90% in-patients with peptic ulcer. It causes MALT-lymphoma and gastric cancer.

They pass through mucus, colonize gastric cells, and cause inflammation of gastric mucosa, which usually lead to chronic gastritis. The most favorable conditions for the growth of this infection is temperature between 37-42 °C and Ph 4-6, but it can grow when Ph around 2.

It is known, that Helicobacter pylori infection cause acute, chronic gastritis, duodenitis, and it leads to decrement of resistance abilities of mucosa in inflammation zone, to atrophia which can be transformed to metaplastic changes of gastric cells, or/and ulceration.

Helicobacter pylori can live in the stomach of many inpiduals during lifetime. This bacterium can be found in mucus in-patients with duodenal ulcer disease in 100% of cases, and in 80-90% in-patients with peptic ulcer.

It causes MALT-lymphoma and gastric cancer. These bacteria are considered as cancerogens of the first class. The management of treatment patients infected by Helicobacter pylori is its eradication. The standard scheme and regimen for eradication consist of two antibiotics and one PPI (proton pomp inhibitor). The most important problem in nowadays is increasing the numbers of Helicobacter pylori resistant antibiotics (nitronidazole, and during last time to clarythrinycin). It leads to failure of treatment. So, the problem of Helicobacter pylori infection is not solved.

The decrement of this rate depends on effectivity of eradication of Helicobacter pylori infection.

The excepting results of this investigation are:


– definition of risk factors for Helicobacter pylori infection;
– elucidation of its transmission;
– clarification of the prevalence of Helicobacter pylori infection in Kazakhstan;
– determination of the peculiarities of Helicobacter pylori-associated diseases
– in population of Kazakhstan;
– The development of the schemes and regimens of the treatment of H.pylori-associated diseases in Kazakhstan.


Back